Raymond James Trust’s Guardant Health GH Stock Holding History

Raymond James Trust’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,434	Closed	-$218K	–	1145
2021 Q1	$218K	Buy	+1,434	New	+$217K	0.01%	987

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Raymond James Trust's GH Position: Q2 2021 in Review

Raymond James Trust sold out of Guardant Health (GH) in Q2 2021, closing a stake of 1,434 shares — an estimated $218K sold.

Raymond James Trust first reported a position in GH in Q1 2021 and held it in 1 quarter. The position peaked at $218K in Q1 2021. 416 funds tracked by Wall St. Rank hold GH as of Q2 2021.

Raymond James Trust reported no remaining Guardant Health position as of Q2 2021 after selling out during the quarter.
Raymond James Trust sold 1,434 Guardant Health shares in Q2 2021, an estimated $218K.
Raymond James Trust first reported a position in Guardant Health in Q1 2021 and held it in 1 quarter.
Raymond James Trust's Guardant Health position peaked at $218K in Q1 2021.
416 funds tracked by Wall St. Rank held Guardant Health as of Q2 2021.

Based on Raymond James Trust's 13F filing for Q2 2021, filed 20 Jul 2021.